- Home
- GSIW vs INDP Comparison
GSIW vs INDP Comparison
Compare GSIW & INDP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GSIW
- INDP
- Stock Information
- Founded
- GSIW 2016
- INDP 2000
- Country
- GSIW Hong Kong
- INDP United States
- Employees
- GSIW N/A
- INDP N/A
- Industry
- GSIW
- INDP Biotechnology: Pharmaceutical Preparations
- Sector
- GSIW
- INDP Health Care
- Exchange
- GSIW Nasdaq
- INDP Nasdaq
- Market Cap
- GSIW 10.5M
- INDP 10.2M
- IPO Year
- GSIW 2023
- INDP N/A
- Fundamental
- Price
- GSIW $0.57
- INDP $0.94
- Analyst Decision
- GSIW
- INDP Strong Buy
- Analyst Count
- GSIW 0
- INDP 2
- Target Price
- GSIW N/A
- INDP $8.50
- AVG Volume (30 Days)
- GSIW 156.5K
- INDP 24.7K
- Earning Date
- GSIW 12-31-2024
- INDP 11-12-2024
- Dividend Yield
- GSIW N/A
- INDP N/A
- EPS Growth
- GSIW N/A
- INDP N/A
- EPS
- GSIW N/A
- INDP N/A
- Revenue
- GSIW $1,408,469.00
- INDP N/A
- Revenue This Year
- GSIW N/A
- INDP N/A
- Revenue Next Year
- GSIW N/A
- INDP N/A
- P/E Ratio
- GSIW N/A
- INDP N/A
- Revenue Growth
- GSIW N/A
- INDP N/A
- 52 Week Low
- GSIW $0.53
- INDP $0.84
- 52 Week High
- GSIW $15.99
- INDP $3.10
- Technical
- Relative Strength Index (RSI)
- GSIW 36.17
- INDP 34.68
- Support Level
- GSIW $0.55
- INDP $0.94
- Resistance Level
- GSIW $0.64
- INDP $1.06
- Average True Range (ATR)
- GSIW 0.06
- INDP 0.05
- MACD
- GSIW 0.04
- INDP 0.00
- Stochastic Oscillator
- GSIW 16.67
- INDP 0.00
About GSIW Garden Stage Limited
Garden Stage Ltd is a Hong Kong-based financial services provider principally engaged in the provision of placing and underwriting services; securities dealing and brokerage services; and asset management services. Its business is carried out through its wholly owned Operating Subsidiaries: a) I Win Securities, which is licensed to conduct Type 1 (dealing in securities) regulated activities under the SFO in Hong Kong, and b) I Win Asset Management, which is licensed to conduct Type 4 (advising on securities) and Type 9 (asset management) regulated activities under the SFO in Hong Kong.
About INDP Indaptus Therapeutics Inc.
Indaptus Therapeutics Inc is a pre-clinical biotechnology company engaged in developing a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. It has developed a proprietary platform that exploits bacteria's natural ability to activate both innate and adaptive cellular immune pathways. The company's pre-clinical candidate Decoy20, has the ability to elicit single-agent activity and durable anti-tumor responses in the combination setting against colorectal, hepatocellular, pancreatic carcinoma, and non-Hodgkin's lymphoma models.